Cargando…
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it awakens and provokes a clinical attack with attendant morbidity, risk of mortality, and opportunities for onward t...
Autores principales: | Baird, J. Kevin, Battle, Katherine E., Howes, Rosalind E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778616/ https://www.ncbi.nlm.nih.gov/pubmed/29357870 http://dx.doi.org/10.1186/s12936-018-2190-z |
Ejemplares similares
-
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria
por: Baird, Kevin
Publicado: (2015) -
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function
por: Choi, Sungim, et al.
Publicado: (2022) -
Plasmodium vivax Malaria Relapses after Primaquine Prophylaxis
por: Reddy, Pavani, et al.
Publicado: (2006) -
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria
por: Baird, J. Kevin, et al.
Publicado: (2018) -
Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria
por: Taylor, Walter R. J., et al.
Publicado: (2021)